1. Губергриц Н.Б., Бен Хмида Макрем Бен Мекк. Билиарный сладж: констатировать или лечить? Сучасна гастроэнтерология. 2005; 4 (24): 9–19.
2. Герок В., Блюм Х.Е. Заболевания печени и желчевыделительной системы. Пер. с нем. Под общ. ред. В.Т.Ивашкина, А.А.Шептулина. М.: МЕДпресс-информ, 2009.
3. Иванченкова Р.А. Хронические заболевания желчевыводящих путей. М.: Атмосфера, 2006.
4. Иванченкова Р.А., Атькова Е.Р. Консервативная терапия хронических заболеваний желчного пузыря (желчнокаменной болезни и холестероза желчного пузыря). Практическое руководство для врачей. М., 2011.
5. Ильченко А.А. Классификация желчнокаменной болезни. Тер. архив. 2004; 2: 75–9.
6. Ильченко А.А. Современный взгляд на проблему билиарного сладжа. Рус. мед. журн. Болезни органов пищеварения. 2010; 28: 1707–12.
7. Лейшнер У. Практическое руководство по заболеваниям желчных путей. М.: ГЭОТАР-МЕД, 2001.
8. Успенская Ю.Б. Состояние желчевыводящих путей у беременных. Материалы научно-практической конференции «Актуальные вопросы гастроэнтерологии. Василенковские чтения», 2010; с. 101.
9. Acalovschi M. Cholesterol gallstones: from epidemiology to prevention. Postgrad Med J 2001; 77: 221–9.
10. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917–23.
11. Baisini, O, Benini R, Petraglia F, Kuhnz W et al. Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. Eur J Clin Pharmacol 2004; 60: 481–7.
12. Barbara L, Sama C, Morselli Labate AM et al. A population study on the prevalence of gallstone disease: the Sirmione study. Hepatology 1987; 7: 913–7.
13. Basso L, McCollum PT, Darling MR et al. A descriptive study of pregnant women with gallstones. Relation to dietary and social habits, ducation, physical activity, height, and weight. Eur J Epidemiol 1992; 8: 629–33.
14. Boffelli D, Zajchowski DA, Yang Z, Lawn RM. Estrogen modulation of apolipoprotein (a) expression. Identification of a regulatory element. J Biol Chem 1999; 274 (22): 15569–74.
15. Caprio M, Feve B, Claes A et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21 (9): 2185–94.
16. Caprio M, Zennaro MC, Fеve B et al. Potencial role of progestagens in the control of adipose tissue and salt sensitivity via interaction with the mineralocorticoid receptor. Climacteric 2008; 11 (3): 258–64.
17. Caruso MG, Giangrande M, Clemente C et al. Serum lipids and biliary sludge during pregnancy. Minerva Gastroenterol Dietol 1993; 39 (2): 67–70.
18. Davis RA, Elliott TS, Lattier GR, Showalter RB, Kern F. Regulation of bile acid synthesis via direct effects on the microsomal membrane. Biochemistry 1986; 25 (7): 1632–6.
19. Dhiman R, Sarkar P, Sharma A et al. Alterations in Gallbladder Emptying and Bile Retention in the Absence of Changes in Bile Lithogenicity in Postmenopausal Women on Hormone Replacement Therapy. Digest Diseases Sci 2004; 49 (7–8): 1335–41.
20. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic stady of norplant, depot medroxyprogesterone acetate. J Obstet Gynecol Res 2000; 26: 17–26.
21. Etminan M, Delaney JA, Bressler B, Brophy JM. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. CMAJ 2011; 183 (8): 899–904.
22. Everson GT. Gallbladder function in gallstone disease. 
Gastroenterol Clin North Am 1991; 20 (1): 85–110.
23. Frederic S, Hould MD, Gerald M et al. Progesterone receptors regulate gallbladder motility. J Surg Res 1988; 45 (Issue 6): 505–12.
24. Gilat T, Konikoff F. Pregnancy and the biliary tract. Can J Gastroenterol 2000; 14 (Suppl. D:55D).
25. Heikkinen J, Ylöstalo P, Mäentausta O, Jänne O. Serum bileacids during biphasic contraceptive treatment with ethinyl estradiol and norgestrel. Contraception 1982; 25 (Issue 1): 89–95.
26. Henriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen-induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J Clin Invest 1989; 84 (3): 811–6.
27. Kern F, Everson GT, DeMark B et al. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Invest 1981; 68: 1229–42.
28. Khan MK, Jalil MA, Khan MS. Oral contraceptives in gall stone diseases. Mymensingh Med J 2007; 16 (Suppl. 2): S40–5.
29. Kiaii B, Xu QW, Shaffer EA. The basis for progesterone impairment of gallbladder contractility in male guinea pigs in vitro. J Surg Res 1998; 79 (2): 97–102.
30. Kline LW, Karpinski E. Progesterone inhibits gallbladder motility through multiple signaling pathways. Steroids 2005; 70 (Issue 9): 673–9.
31. Kline LW, Karpinski E. 17b-Estradiol relaxes cholecystokinin- and KCl-induced tension in male guinea pig gallbladder strips. Steroids 2011; 76 (6): 553–7.
32. Ko CW, Beresford SA, Schulte SJ. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005; 41 (2): 359–65.
33. Lindseth G, Bird-Baker MY. Risk factors for cholelithiasis in pregnancy. Res Nurs Health 2004; 27: 382–91.
34. Liu B, Beral V, Balkwill A et al. Million Women Study Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337: a386.
35. Mamdani MM, Tu K, C van Walraven et al. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ 2000; 162 (10): 1421–4.
36. Maringhini A, Ciambra M, Baccelliere P et al. Biliary sludge and gallstones in preg-nancy: incidence, risk factors, and natural history. Ann Intern Med 1993; 119 (2): 116–20.
37. Ness GC, Chambers CM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 2000; 224 (1): 8–19.
38. Philipp BW, Shapiro DJ. Estrogen regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and acetyl-CoA carboxylase in xenopus laevis. J Biol Chem 1981; 256 (6): 2922–7.
39. Portincas P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006; 368: 230–39.
40. Ropponen A, Sund R, Riikonen S et al. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology 2006; 43 (4): 723–28.
41. Royal College of General Practitioners. Oral Contracepties and Health London, England: Pitman Medical 1974: 57–9.
42. Royal College of General Practitioners. Oral Contraception Study. Oral contraceptives and gallbladder disease. Lancet 1982; 957–9.
43. Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500–11.
44. Schwenk T. Women's Health Initiative update: Estrogen Therapy Increases Risk for Gallbladder Disease. J Watch Women's Health.
45. Scragg RKR, McMichael AJ, Seamark RF. Oral contraceptives, pregnancy, and endogenous oestrogen in gall stone disease – a case-control study. BMJ 1984; 288: 1795–9.
46. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2005; 7: 132–40.
47. Simon JA, Donald B et al. Effect of Estrogen plus Progestin on Risk for Biliary Tract Surgery in Postmenopausal Women with Coronary Artery Disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001; 135 (7): 493–501.
48. Simon JA. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012; 15 (Suppl. 1): 3–10.
49. Sitruk-Ware R. New progestagens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004; 21 (13): 865–83.
50. Srivastava RA, Srivastava N, Averna M et al. Estrogen up-regulates Apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor a-mediated pathway. J Biol Chem 1997; 272 (52): 33360–6.
51. Strom BL, Tamragouri RN, Morse ML et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39: 335–41.
52. The World Health Organization. Cardiovascular disease and steroid hormone contraception. Technical Report Series. 877. 
Geneva: The Organization, 1998.
53. Thijs C, Knipschild P, Leffers P. Pregnancy and gallstone disease-an empiric demonstration of the importance of specificationof risk periods. Am J Epidemiol 1991; 134: 186–95.
54. Thijs C, Knipschild P. Oral Contraceptives and the Risk of Gallbladder Disease: A Meta-Analysis. Am J Public Health 1993; 83 (8): 1113–9.
55. Tierney S, Nakeeb A, Won O et al. Progesterone alters biliary flow dynamics. Ann Surg 1999; 229 (2): 205–9.
56. Valdivieso V, Covarrubias C, Siegel F et al. Pregnancy and cholelithiasis:pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 1993; 17: 1–4.
57. VanErpecum KJ, Vanberge Henegouwen GP, Verschoor I et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482–8.

Ю.Б.Успенская1, И.В.Кузнецова2 

1. ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ; 
2. ГОУ ДПО Российская медицинская академия последипломного образования, Москва